STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

GLTO director equity: 8,032 restricted shares and Series C stake

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Galecto, Inc. (GLTO)8,032 shares of restricted common stock, with one quarter scheduled to vest on August 22, 2026 and the remaining three quarters vesting in equal monthly installments over the following three years, conditioned on continued service to the company. The insider also beneficially owns 129 shares of Series C Preferred Stock, which are convertible into 129,000 shares of common stock after stockholders approve the conversion, subject to stated limitations. The underlying common shares tied to this preferred stock follow the same vesting schedule and service-based conditions.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Bruno Julianne

(Last) (First) (Middle)
C/O GALECTO, INC.,
75 STATE STREET, SUITE 100

(Street)
BOSTON MA 02109

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
11/10/2025
3. Issuer Name and Ticker or Trading Symbol
Galecto, Inc. [ GLTO ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 8,032(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Preferred Stock (2)(3) (2) Common Stock 129,000 (2) D
Explanation of Responses:
1. Consists of 8,032 shares of restricted Common Stock, one quarter of which will vest on August 22, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer.
2. Following stockholder approval of the conversion of Series C Preferred Stock into shares of Common Stock, each share of Series C Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations.
3. Consists of 129 shares of Series C Preferred Stock. One quarter of the underlying shares of Common Stock will vest on August 22, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Lori Firmani, attorney-in-fact 11/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider ownership is disclosed for Galecto, Inc. (GLTO)?

The reporting person, who is a director of Galecto, Inc., beneficially owns 8,032 shares of restricted common stock and 129 shares of Series C Preferred Stock, which are convertible into 129,000 shares of common stock after required stockholder approval.

How do the restricted common shares for the GLTO director vest?

The 8,032 restricted common shares vest over time: one quarter vests on August 22, 2026, and the remaining three quarters vest in equal monthly installments over the next three years, subject to the director’s continued service to Galecto.

What are the terms of the Series C Preferred Stock reported for GLTO?

The insider holds 129 shares of Series C Preferred Stock. After stockholders approve the conversion, each preferred share will automatically convert into 1,000 shares of common stock, for a total of 129,000 underlying common shares, subject to certain limitations.

Do the GLTO preferred stock conversion shares have a vesting schedule?

Yes. One quarter of the underlying common shares from the Series C Preferred Stock will vest on August 22, 2026, and the remaining three quarters will vest in equal monthly installments over the following three years, contingent on the reporting person’s continued service.

What role does the reporting person hold at Galecto, Inc. (GLTO)?

The reporting person is identified as a director of Galecto, Inc., and the equity awards disclosed are tied to their ongoing service to the company.

Galecto Inc.

NASDAQ:GLTO

GLTO Rankings

GLTO Latest News

GLTO Latest SEC Filings

GLTO Stock Data

36.45M
1.54M
3.68%
12.25%
0.95%
Biotechnology
Pharmaceutical Preparations
Link
Denmark
BOSTON